<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with <z:e sem="disease" ids="C0151773" disease_type="Disease or Syndrome" abbrv="">hypocellular bone marrow</z:e> (BM) is often difficult to distinguish from <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) </plain></SENT>
<SENT sid="1" pm="."><plain>Furthermore, the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with low blast counts and <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype may be problematic </plain></SENT>
<SENT sid="2" pm="."><plain>These issues highlight the need for a reliable marker for the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>This study was conducted to determine if changes of <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in any of the four selected genes would be useful markers for differentiation of hypoplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> from AA, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> from benign disease, as well as to investigate whether <z:chebi fb="2" ids="33699">mRNA</z:chebi> expressions differ between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> risk subgroups </plain></SENT>
<SENT sid="4" pm="."><plain>Thirty-five patients diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 27 patients with AA and 17 patients with benign diseases were included </plain></SENT>
<SENT sid="5" pm="."><plain>The CD34, RAB20, PU.1 and GFI1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels were measured by real-time RT-PCR </plain></SENT>
<SENT sid="6" pm="."><plain>The CD34 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expressions in hypoplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were higher than those found in AA </plain></SENT>
<SENT sid="7" pm="."><plain>PU.1 and GFI1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expressions were significantly lower in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with low blast counts and <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype than those of benign disease </plain></SENT>
<SENT sid="8" pm="."><plain>High-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> showed higher CD34 expressions than those of low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>This study suggests that measurement of CD34 and GFI1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expressions could be useful as a diagnostic and prognostic marker for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>